2014 Generics Sales: $6.6 billion +6%
Worldwide Market Share: 8.9%
The drugmaker once known as Actavis is a pretty different-looking company than it was in 2014--and the changes aren't over. But let's wind back the clock a bit.
At the end of last year, Actavis boasted a U.S. portfolio of about 250 generic pharma product families, including some big guns. Copies of Eli Lilly ($LLY) antidepressant Cymbalta, Endo ($ENDP) topical patch Lidoderm, and Johnson & Johnson ($JNJ) ADHD treatment Concerta helped lead the company's lineup, as did a knock off of Pfizer's ($PFE) Celebrex, which Actavis that April won the right to launch in a settlement.
Some of those families it picked up through M&A activity. In April, 2014, it shelled out $100 million to buy a small generics maker, Silom, in Thailand; the deal vaulted the company into the top 5 generics makers in the country, with the pair boasting more than three dozen marketed products combined.
The pharma also rolled out 500 generic products around the world in 2014. Others, though, were stopped in their tracks by litigation. In June 2014, California drugmaker Vivus ($VVUS) slapped Actavis with a patent infringement suit over its ANDA for struggling obesity pill Qsymia, automatically staying FDA approval for 30 months.
Actavis also lost a patent lawsuit against Depomed ($DEPO), the maker of a shingles pain drug, Gralise, that it had wanted to copy. In August, 2014, a judge from the U.S. District Court in New Jersey ruled that Actavis' filing infringed all 7 of Depomed's patents on the product--a decision that will protect Gralise's market exclusivity until 2024.
Of course, going forward, Actavis--now called Allergan ($AGN) after the $66 billion acquisition it closed earlier this year--will only be finding itself on the other side of the coin. After wrapping up the Allergan transaction, the company agreed to sell off its generics business to industry giant Teva ($TEVA) for $40 billion-plus.
-- Carly Helfand (email | Twitter)
About that brand/generics hybrid thing? Make that brands only, Allergan says with Teva deal
Depomed scores a win in its epic struggle to fend off Gralise copycats
Vivus hits Actavis with Qsymia patent-infringement lawsuit
Pfizer concedes Celebrex to Actavis, Teva after 2015 patent strike-down
Actavis shells out $100M for Thai generics maker in bid for Southeast Asia growth